Stock Trading Canary

United States · SEC Form 4 · Snapshot date: 2026-10-18 · Built: 2026-10-18 · 中文

← United States · Coverage record

US · SEC FORM 4

Immuneering Corp

IMRX · Nasdaq · CIK 0001790340 · Healthcare · Biotechnology

INSIDER SIGNAL

42.5 / 100

2 buyers · 2 purchase transaction lines · $36.0K gross purchase

WHY THIS SIGNAL?

Buyer breadthLow
Purchase sizeLow
RoleModerate
RecencyLow
ConvictionStrong
Score anatomy

Each bar shows the contribution to the current score; the weights and formula stay unchanged.

Cluster+14.0 / 35
Purchase size+4.1 / 25
Role+13.0 / 20
Recency+1.4 / 10
Conviction+10.0 / 10

What is holding the score back?

  • ⚠ Cluster breadth is moderate · 2 insider(s), not 4+
  • ⚠ Purchase size is modest relative to the model scale
  • ⚠ Role scores low · most senior buyer: PRESIDENT AND CEO (CEO, chair and 10% owners score lowest)
  • ⚠ Purchase activity is becoming less recent

Purchase-size comments are relative to the model scale. Average daily volume is a separate market-context diagnostic.

US-v1.2 ranks qualifying equity purchases under the current 180-day rules. The score is a research priority, not a return forecast or probability. Backtests have not shown that a higher US score is followed by better returns.

Insider activity timeline

Owner lanes show the latest 180 days. Symbol shape identifies the transaction type; sales remain context only.

AprMayJunJulAugSepOct
Zeskind Benjamin J.PRESIDENT AND CEO
●
Hall Brett MatthewCHIEF SCIENTIFIC OFFICER
●
● Purchase▼ Sale○ Other

—

Purchase breadth & concentration

QUALIFYING BUYERS2
PURCHASE CONCENTRATION70%Largest buyer: Hall Brett Matthew · $25.0K
CLUSTER BUYING · 15D2 insidersPeak activity: 2026-06-15–2026-06-23

Roles in the peak window: CHIEF SCIENTIFIC OFFICER, PRESIDENT AND CEO. Concentration uses priced qualifying P lines only and does not change the saved score.

SIGNAL HISTORY

42.5 / 100

Latest recorded score

↓ -0.1 ptsversus the previous recorded snapshot
  1. 42.8
  2. 42.7
  3. 42.7
  4. 42.6
  5. 42.5

Only scores saved when a full US scoring run completed are shown; gaps are not reconstructed.

Recent Form 4 activity

7Purchases
0Sales
1Other Form 4 lines
8SEC filings · 365 days
BUYING2 qualifying P line(s) · 180 days
SELLING0 sale line(s) · context only
OTHER0 exercise / withholding / award / gift / other lines
10b5-1 / PLANNEDNot assessed

P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.

Market context

Market context provides additional background on recent price performance and risk. It does not affect the Insider Signal.

Price performance

1M
-13.8%
3M
-23.6%
6M
-28.6%
12M
-39.4%

Volatility & liquidity

Volatility
102.8%
Beta
—
Avg daily value
USD 2.8M

Valuation

Market cap
—
P/E
—

Fundamentals

Profit margin
—
ROE
-25.6%
Industry
Biotechnology

Market data

Price data up to: 2026-10-11 · Price source: OpenBB/yfinance; volume from price cache (yfinance) · From SEC filings: ROE · Fiscal year ended: 2025-12-31 · Status: PASS

Short interest

Short interest is external context reported to FINRA by broker-dealers. It does not affect the Insider Signal.

Shares short
15,492,438
Previous report
15,550,745
Avg daily volume
639,765
Days to cover
24.2

FINRA settlement date: 2026-09-30 · Captured 2026-10-12 · FINRA equity short interest ↗. A share count, published about a week after each of two settlement dates a month; not a percentage of shares outstanding.

Historical equity purchases

Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.

Transaction dateReporting ownerTypeSecuritySharesAvg. priceApprox. valueSource
2026-06-23Zeskind Benjamin J.Purchase (P)Class A Common Stock2,400USD 4.56USD 10,944SEC filing ↗
2026-06-15Hall Brett MatthewPurchase (P)Class A Common Stock6,035USD 4.15USD 25,045SEC filing ↗
2026-01-16Brakewood Harold EugenePurchase (P)Class A Common Stock5,250USD 4.76USD 24,990SEC filing ↗
2026-01-15Schall Thomas J.Purchase (P)Class A Common Stock21,645USD 4.67USD 101,082SEC filing ↗
2026-01-15Hall Brett MatthewPurchase (P)Class A Common Stock2,298USD 4.57USD 10,502SEC filing ↗
2026-01-13Neufeld Leah RPurchase (P)Class A Common Stock2,626USD 4.15USD 10,898SEC filing ↗
2026-01-12Feinberg PeterPurchase (P)Class A Common Stock20,000USD 4.35USD 87,000SEC filing ↗
2025-10-03Feinberg PeterPurchase (P)Class A Common Stock7,500USD 6.67USD 50,025SEC filing ↗
2025-10-01Neufeld Leah RPurchase (P)Class A Common Stock800USD 6.38USD 5,104SEC filing ↗
2025-10-01Morales MalloryPurchase (P)Class A Common Stock300USD 6.39USD 1,917SEC filing ↗
2025-10-01Bookman MichaelPurchase (P)Class A Common Stock1,020USD 6.83USD 6,967SEC filing ↗
2025-09-30Feinberg PeterPurchase (P)Class A Common Stock7,500USD 7.03USD 52,725SEC filing ↗
2025-09-29Feinberg PeterPurchase (P)Class A Common Stock5,000USD 7.18USD 35,900SEC filing ↗
2025-07-02Neufeld Leah RPurchase (P)Class A Common Stock700USD 3.57USD 2,499SEC filing ↗
2025-07-02HAUSMAN DIANAPurchase (P)Class A Common Stock5,500USD 3.61USD 19,860SEC filing ↗

Form 4 evidence

8 transaction lines in the latest 365-day window; 97 in local history.

DateOwnerTypeSecuritySharesAvg. priceApprox. valueSource
2026-06-23Zeskind Benjamin J.Purchase (P)Class A Common Stock2,400USD 4.56USD 10,944SEC filing ↗
2026-06-15Hall Brett MatthewPurchase (P)Class A Common Stock6,035USD 4.15USD 25,045SEC filing ↗
2026-03-13Neufeld Leah RAward / grant (A)Class A Common Stock3,628USD 4.29USD 15,564SEC filing ↗
Show recent Form 4 evidence (8 grouped rows)
DateOwnerTypeSecuritySharesAvg. priceApprox. valueSource
2026-06-23Zeskind Benjamin J.Purchase (P)Class A Common Stock2,400USD 4.56USD 10,944SEC filing ↗
2026-06-15Hall Brett MatthewPurchase (P)Class A Common Stock6,035USD 4.15USD 25,045SEC filing ↗
2026-03-13Neufeld Leah RAward / grant (A)Class A Common Stock3,628USD 4.29USD 15,564SEC filing ↗
2026-01-16Brakewood Harold EugenePurchase (P)Class A Common Stock5,250USD 4.76USD 24,990SEC filing ↗
2026-01-15Schall Thomas J.Purchase (P)Class A Common Stock21,645USD 4.67USD 101,082SEC filing ↗
2026-01-15Hall Brett MatthewPurchase (P)Class A Common Stock2,298USD 4.57USD 10,502SEC filing ↗
2026-01-13Neufeld Leah RPurchase (P)Class A Common Stock2,626USD 4.15USD 10,898SEC filing ↗
2026-01-12Feinberg PeterPurchase (P)Class A Common Stock20,000USD 4.35USD 87,000SEC filing ↗

Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.

Snapshot & identity

Snapshot date2026-10-18
Ranking versionUS-v1.2
Data qualityPASS ELIGIBLE · —
TickerIMRX
CIK0001790340
SectorHealthcare
IndustryBiotechnology Yahoo Finance
SEC SIC2834 Pharmaceutical Preparations
ExchangeNasdaq

Data coverage

Local Form 4 history97 transaction lines from 2021-08-03 to 2026-06-23
61 P purchase lines · 13 S sale lines · 23 other lines
SEC company submissionsOpen SEC filings ↗

Local ledger as of 2026-10-18. Mapping status is an audit field and does not erase SEC filing evidence.